DefinitionThis section has been translated automatically.
Virustatic. Non-nucleoside inhibitor of the reverse transcriptase of HIV.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in patients > 3 years.
You might also be interested in
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated in pregnancy (reproductive toxicity in animal tests, insufficient data available).
Dosage and method of useThis section has been translated automatically.
Adults/adolescents/children > 40 kg bw: 1 time/day 600 mg p.o. (in combination with protease inhibitors and/or nucleoside reverse transcriptase inhibitors (NRTI) of HIV.
Dose reduction in children > 3 yrs and patients < 40 kg bw: Pat. with 32.5-40 kg bw: 1 time/day 400 mg p.o., 25-32 kg bw: 1 time/day 350 mg p.o., 20-25 kg bw: 1 time/day 300 mg p.o., 15-20 kg bw: 1 time/day 250 mg p.o., 13-15 kg bw: 1 time/day 200 mg p.o.
Undesirable effectsThis section has been translated automatically.
Gastrointestinal symptoms like nausea (5-10% of patients), headache (5%), dizziness (5-10%), fatigue (5%), cutaneous NW (10-15% of patients) like erythema, erythema exsudativum multiforme, erythema nodosum, urticaria.
ContraindicationThis section has been translated automatically.
Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 3 years. Comedication with rifampicin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam) ergotamine derivatives, astemizole, etc.
PreparationsThis section has been translated automatically.
Sustiva
Prof. Dr. med. Peter Altmeyer